Clinical utility of sympathetic blockade in cardiovascular disease management

References

• Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of cardiology foundation/American heart association task force on practice guidelines. J Am Coll Cardiol. 2013;62:e147–e239.
   PubMed Web of Science ®Google Scholar
• Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American college of cardiology/american heart association task force on practice guidelines. J Am Coll Cardiol. 2014;64:e139–e228.
   PubMed Web of Science ®Google Scholar
• American College of Emergency P, Society for Cardiovascular A, Interventions, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American college of cardiology foundation/American heart Association task force on practice guidelines. J Am Coll Cardiol. 2013;61:e78–e140.
   PubMed Web of Science ®Google Scholar
• Task Force M, Montalescot G, Sechtem U, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European society of cardiology. Eur Heart J. 2013;34:2949–3003.
   PubMed Web of Science ®Google Scholar
• Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the task force for the Management of arterial hypertension of the european society of hypertension (ESH) and of the European society of cardiology (ESC). Eur Heart J. 2013;34:2159–2219.
   PubMed Web of Science ®Google Scholar
• Leineweber K, Wangemann T, Giessler C, et al. Age-dependent changes of cardiac neuronal noradrenaline reuptake transporter (uptake1) in the human heart. J Am Coll Cardiol. 2002;40:1459–1465.
   PubMed Web of Science ®Google Scholar
• Narkiewicz K, Winnicki M, Schroeder K, et al. Relationship between muscle sympathetic nerve activity and diurnal blood pressure profile. Hypertension. 2002;39:168–172.
   PubMed Web of Science ®Google Scholar
• Navar LG. Physiology: hemodynamics, endothelial function, renin-angiotensin-aldosterone system, sympathetic nervous system. J Am Soc Hypertens. 2014;8:519–524.
   PubMed Web of Science ®Google Scholar
• Mano T, Iwase S, Toma S. Microneurography as a tool in clinical neurophysiology to investigate peripheral neural traffic in humans. Clin Neurophysiol. 2006;117:2357–2384.
   PubMed Web of Science ®Google Scholar
• Verberne HJ. Assessment of cardiac sympathetic innervation with 123I-mIBG SPECT comes to life: need for standardization! Eur Heart J Cardiovasc Imaging. 2016;17:391–392.
   PubMed Web of Science ®Google Scholar
• Bristow MR, Ginsburg R, Minobe W, et al. Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. N Engl J Med. 1982;307:205–211.
   PubMed Web of Science ®Google Scholar
• Baker AJ. Adrenergic signaling in heart failure: a balance of toxic and protective effects. Pflugers Arch. 2014;466:1139–1150.
   PubMed Web of Science ®Google Scholar
• Jensen BC, Swigart PM, De Marco T, et al. Alpha1-Adrenergic receptor subtypes in nonfailing and failing human myocardium. Circ Heart Fail. 2009;2:654–663.
   PubMed Web of Science ®Google Scholar
• Grassi G. Sympathetic overdrive and cardiovascular risk in the metabolic syndrome. Hypertens Res. 2006;29:839–847.
   PubMed Web of Science ®Google Scholar
• Masuo K, Mikami H, Ogihara T, et al. Sympathetic nerve hyperactivity precedes hyperinsulinemia and blood pressure elevation in a young, nonobese Japanese population. Am J Hypertens. 1997;10:77–83.
   PubMed Web of Science ®Google Scholar
• Narkiewicz K, Kato M, Phillips BG, et al. Leptin interacts with heart rate but not sympathetic nerve traffic in healthy male subjects. J Hypertens. 2001;19:1089–1094.
   PubMed Web of Science ®Google Scholar
• Egan BM, Basile J, Chilton RJ, et al. Cardioprotection: the role of beta-blocker therapy. J Clin Hypertens. 2005;7:409–416.
   PubMedGoogle Scholar
• Ybanez N, Agrawal V, Tranmer BI, et al. Severe hypokalemia in a patient with subarachnoid hemorrhage. Am J Kidney Dis. 2014;63:530–535.
   PubMed Web of Science ®Google Scholar
• Cruickshank JM. Beta-blockers and diabetes: the bad guys come good. Cardiovasc Drugs Ther. 2002;16:457–470.
   PubMed Web of Science ®Google Scholar
• Julius S, Jamerson K. Sympathetics, insulin resistance and coronary risk in hypertension: the ‘chicken-and-egg’ question. J Hypertens. 1994;12:495–502.
   PubMed Web of Science ®Google Scholar
• Poitras VJ, Pyke KE. The impact of acute mental stress on vascular endothelial function: evidence, mechanisms and importance. Int J Psychophysiol. 2013;88:124–135.
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health and Human Services. How tobacco smoke causes disease: the biology and behavioral basis for smoking-attributable disease: A report of the surgeon general. Atlanta (GA): U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2010.
   Google Scholar
• Klein LW, Pichard AD, Holt J, et al. Effects of chronic tobacco smoking on the coronary circulation. J Am Coll Cardiol. 1983;1:421–426.
   PubMed Web of Science ®Google Scholar
• Grassi G, Dell’Oro R, Facchini A, et al. Effect of central and peripheral body fat distribution on sympathetic and baroreflex function in obese normotensives. J Hypertens. 2014;22:2363–2369.
   Web of Science ®Google Scholar
• Warner A, Mittag J. Thyroid hormone and the central control of homeostasis. J Mol Endocrinol. 2012;49:R29–R35.
   PubMed Web of Science ®Google Scholar
• Lopez-Sendon J, Swedberg K, McMurray J, et al. Expert consensus document on beta-adrenergic receptor blockers. Eur Heart J. 2004;25:1341–1362.
   PubMed Web of Science ®Google Scholar
• Hawkins NM, Petrie MC, Jhund PS, et al. Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. Eur J Heart Fail. 2009;11:130–139.
   PubMed Web of Science ®Google Scholar
• Reddel HK, Bateman ED, Becker A, et al. A summary of the new GINA strategy: a roadmap to asthma control. Eur Respir J. 2015;46:622–639.
   PubMed Web of Science ®Google Scholar
• Esler M, Jennings G, Korner P, et al. Assessment of human sympathetic nervous system activity from measurements of norepinephrine turnover. Hypertension. 1988;11:3–20.
   PubMed Web of Science ®Google Scholar
• Schlaich MP, Kaye DM, Lambert E, et al. Relation between cardiac sympathetic activity and hypertensive left ventricular hypertrophy. Circulation. 2003;108:560–565.
   PubMed Web of Science ®Google Scholar
• Lambert E, Straznicky N, Schlaich M, et al. Differing pattern of sympathoexcitation in normal-weight and obesity-related hypertension. Hypertension. 2007;50:862–868.
   PubMed Web of Science ®Google Scholar
• Grassi G. Assessment of sympathetic cardiovascular drive in human hypertension: achievements and perspectives. Hypertension. 2009;54:690–697.
   PubMed Web of Science ®Google Scholar
• Parati G, Lombardi C, Hedner J, et al. Position paper on the management of patients with obstructive sleep apnea and hypertension: joint recommendations by the European society of hypertension, by the European respiratory society and by the members of European COST (COoperation in scientific and technological research) ACTION B26 on obstructive sleep apnea. J Hypertens. 2012;30:633–646.
   PubMed Web of Science ®Google Scholar
• Converse RL Jr., Jacobsen TN, Toto RD, et al. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med. 1992;327:1912–1918.
   PubMed Web of Science ®Google Scholar
• Messerli FH, Bangalore S, Julius S. Risk/benefit assessment of beta-blockers and diuretics precludes their use for first-line therapy in hypertension. Circulation. 2008;117:2706–2715.
   PubMed Web of Science ®Google Scholar
• Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995–1003.
   PubMed Web of Science ®Google Scholar
• Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac outcomes trial-blood pressure lowering arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366:895–906.
   PubMed Web of Science ®Google Scholar
• Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665.
   PubMed Web of Science ®Google Scholar
• Zanchetti A, Bond MG, Hennig M, et al. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European lacidipine study on atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation. 2002;106:2422–2427.
   PubMed Web of Science ®Google Scholar
• Hansson L, Hedner T, Lund-Johansen P, et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet. 2000;356:359–365.
   PubMed Web of Science ®Google Scholar
• Black HR, Elliott WJ, Grandits G, et al. Principal results of the controlled onset verapamil investigation of cardiovascular end points (CONVINCE) trial. JAMA. 2003;289:2073–2082.
   PubMed Web of Science ®Google Scholar
• Wright JT Jr., Bakris G, Greene T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002;288:2421–2431.
   PubMed Web of Science ®Google Scholar
• James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth joint national committee (JNC 8). JAMA. 2014;311:507–520.
   PubMed Web of Science ®Google Scholar
• Weber MA, Schiffrin EL, White WB, et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American society of hypertension and the international society of hypertension. J Clin Hypertens. 2014;16:14–26.
   PubMed Web of Science ®Google Scholar
• Stears AJ, Woods SH, Watts MM, et al. A double-blind, placebo-controlled, crossover trial comparing the effects of amiloride and hydrochlorothiazide on glucose tolerance in patients with essential hypertension. Hypertension. 2012;59:934–942.
   PubMed Web of Science ®Google Scholar
• Bakris GL, Fonseca V, Katholi RE, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA. 2004;292:2227–2236.
   PubMed Web of Science ®Google Scholar
• Okazaki T, Himeno E, Nanri H, et al. Effects of a community-based lifestyle-modification program on cardiovascular risk factors in middle-aged women. Hypertens Res. 2001;24:647–653.
   PubMed Web of Science ®Google Scholar
• Fadl Elmula FE, Jin Y, Yang WY, et al. Meta-analysis of randomized controlled trials of renal denervation in treatment-resistant hypertension. Blood Press. 2015;24:263–274.
   PubMed Web of Science ®Google Scholar
• Frank H, Heusser K, Geiger H, et al. Temporary reduction of blood pressure and sympathetic nerve activity in hypertensive patients after microvascular decompression. Stroke. 2009;40:47–51.
   PubMed Web of Science ®Google Scholar
• Elmer PJ, Obarzanek E, Vollmer WM, et al. Effects of comprehensive lifestyle modification on diet, weight, physical fitness, and blood pressure control: 18-month results of a randomized trial. Ann Intern Med. 2006;144:485–495.
   PubMed Web of Science ®Google Scholar
• Viskin S, Golovner M, Malov N, et al. Circadian variation of symptomatic paroxysmal atrial fibrillation. Data from almost 10 000 episodes. Eur Heart J. 1999;20:1429–1434.
   PubMed Web of Science ®Google Scholar
• Kawashima T. The autonomic nervous system of the human heart with special reference to its origin, course, and peripheral distribution. Anat Embryol. 2005;209:425–438.
   PubMedGoogle Scholar
• Nguyen BL, Fishbein MC, Chen LS, et al. Histopathological substrate for chronic atrial fibrillation in humans. Heart Rhythm. 2009;6:454–460.
   PubMed Web of Science ®Google Scholar
• Chen PS, Chen LS, Fishbein MC, et al. Role of the autonomic nervous system in atrial fibrillation: pathophysiology and therapy. Circ Res. 2014;114:1500–1515.
   PubMed Web of Science ®Google Scholar
• Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37:2893–2962.
   PubMed Web of Science ®Google Scholar
• Nergardh AK, Rosenqvist M, Nordlander R, et al. Maintenance of sinus rhythm with metoprolol CR initiated before cardioversion and repeated cardioversion of atrial fibrillation: a randomized double-blind placebo-controlled study. Eur Heart J. 2007;28:1351–1357.
   PubMed Web of Science ®Google Scholar
• Farshi R, Kistner D, Sarma JS, et al. Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: a crossover open-label study of five drug regimens. J Am Coll Cardiol. 1999;33:304–310.
   PubMed Web of Science ®Google Scholar
• January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American college of cardiology/American heart association task force on practice guidelines and the heart rhythm society. Circulation. 2014;130:e199–e267.
   PubMed Web of Science ®Google Scholar
• Hogarth AJ, Dobson LE, Tayebjee MH. During ablation for atrial fibrillation, is simultaneous renal artery ablation appropriate? J Hum Hypertens. 2013;27:707–714.
   PubMed Web of Science ®Google Scholar
• Canty JM Jr., Duncker DJ. Coronary blood flow and myocardial ischemia. In: Mann DL, Zipes DP, Libby P, Bonow RO, Braunwald E, editors. Braunwald’s heart disease. 10th ed. Vol. 2, Phildelphia (PA): Elsevier; 2015; p. 1029–1056.
   Google Scholar
• Bangalore S, Steg G, Deedwania P, et al. beta-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012;308:1340–1349.
   PubMed Web of Science ®Google Scholar
• Yusuf S, Wittes J, Friedman L. Overview of results of randomized clinical trials in heart disease. II. Unstable angina, heart failure, primary prevention with aspirin, and risk factor modification. JAMA. 1988;260:2259–2263.
   PubMed Web of Science ®Google Scholar
• Chen ZM, Pan HC, Chen YP, et al. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005;366:1622–1632.
   PubMed Web of Science ®Google Scholar
• Kontos MC, Diercks DB, Ho PM, et al. Treatment and outcomes in patients with myocardial infarction treated with acute beta-blocker therapy: results from the American college of cardiology’s NCDR((R)). Am Heart J. 2011;161:864–870.
   PubMed Web of Science ®Google Scholar
• Roffi M, Patrono C, Collet JP, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European society of cardiology (ESC). Eur Heart J. 2016;37:267–315.
   PubMed Web of Science ®Google Scholar
• Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European society of cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18:891–975.
   PubMed Web of Science ®Google Scholar
• Florea VG, Cohn JN. The autonomic nervous system and heart failure. Circ Res. 2014;114:1815–1826.
   PubMed Web of Science ®Google Scholar
• Lee H-Y, Baek SH. Optimal use of beta-blockers for congestive heart failure. Circ J. 2016;80:565–571.
   PubMed Web of Science ®Google Scholar
• Kaye DM, Lefkovits J, Jennings GL, et al. Adverse consequences of high sympathetic nervous activity in the failing human heart. J Am Coll Cardiol. 1995;26:1257–1263.
   PubMed Web of Science ®Google Scholar
• Hjalmarson A, Goldstein S, Fagerberg B, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF study group. JAMA. 2000;283:1295–1302.
   PubMed Web of Science ®Google Scholar
• CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353:9–13.
   Google Scholar
• Packer M, Fowler MB, Roecker EB, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation. 2002;106:2194–2199.
   PubMed Web of Science ®Google Scholar
• Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001;357:1385–1390.
   PubMed Web of Science ®Google Scholar
• Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol or metoprolol European trial (COMET): randomised controlled trial. Lancet. 2003;362:7–13.
   PubMed Web of Science ®Google Scholar
• Flather MD, Shibata MC, Coats AJ, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26:215–225.
   PubMed Web of Science ®Google Scholar
• Beta-Blocker Evaluation of Survival Trial I. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med. 2001;344:1659–1667.
   PubMed Web of Science ®Google Scholar
• Lee HY, Chung WJ, Jeon HK, et al. Impact of the beta-1 adrenergic receptor polymorphism on tolerability and efficacy of bisoprolol therapy in Korean heart failure patients: association between beta adrenergic receptor polymorphism and bisoprolol therapy in heart failure (ABBA) study. Korean J Intern Med. 2016;31:277–287.
   PubMed Web of Science ®Google Scholar
• Bergstrom A, Andersson B, Edner M, et al. Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function. Results of the Swedish Doppler-echocardiographic study (SWEDIC). Eur J Heart Fail. 2004;6:453–461.
   PubMed Web of Science ®Google Scholar
• Hernandez AF, Hammill BG, O’Connor CM, et al. Clinical effectiveness of beta-blockers in heart failure: findings from the OPTIMIZE-HF (Organized program to initiate lifesaving treatment in hospitalized patients with heart failure) registry. J Am Coll Cardiol. 2009;53:184–192.
   PubMed Web of Science ®Google Scholar
• Lund LH, Benson L, Dahlstrom U, et al. Association between use of beta-blockers and outcomes in patients with heart failure and preserved ejection fraction. JAMA. 2014;312:2008–2018.
   PubMed Web of Science ®Google Scholar
• Rain S, Handoko ML, Vonk Noordegraaf A, et al. Pressure-overload-induced right heart failure. Pflugers Arch. 2014;466:1055–1063.
   PubMed Web of Science ®Google Scholar
• Quaife RA, Christian PE, Gilbert EM, et al. Effects of carvedilol on right ventricular function in chronic heart failure. Am J Cardiol. 1998;81:247–250.
   PubMed Web of Science ®Google Scholar
• Provencher S, Herve P, Jais X, et al. Deleterious effects of beta-blockers on exercise capacity and hemodynamics in patients with portopulmonary hypertension. Gastroenterology. 2006;130:120–126.
   PubMed Web of Science ®Google Scholar
• Desai RV, Guichard JL, Mujib M, et al. Reduced right ventricular ejection fraction and increased mortality in chronic systolic heart failure patients receiving beta-blockers: insights from the BEST trial. Int J Cardiol. 2013;163:61–67.
   PubMed Web of Science ®Google Scholar
• Patel P, White DL, Deswal A. Translation of clinical trial results into practice: temporal patterns of beta-blocker utilization for heart failure at hospital discharge and during ambulatory follow-up. Am Heart J. 2007;153:515–522.
   PubMed Web of Science ®Google Scholar
• Prins KW, Neill JM, Tyler JO, et al. Effects of beta-blocker withdrawal in acute decompensated heart failure: a systematic review and meta-analysis. JACC Heart Fail. 2015;3:647–653.
   PubMed Web of Science ®Google Scholar
• Fonarow GC, Abraham WT, Albert NM, et al. Influence of beta-blocker continuation or withdrawal on outcomes in patients hospitalized with heart failure: findings from the OPTIMIZE-HF program. J Am Coll Cardiol. 2008;52:190–199.
   PubMed Web of Science ®Google Scholar
• Butler J, Young JB, Abraham WT, et al. Beta-blocker use and outcomes among hospitalized heart failure patients. J Am Coll Cardiol. 2006;47:2462–2469.
   PubMed Web of Science ®Google Scholar
• McAlister FA, Wiebe N, Ezekowitz JA, et al. Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med. 2009;150:784–794.
   PubMed Web of Science ®Google Scholar
• Cullington D, Goode KM, Clark AL, et al. Heart rate achieved or beta-blocker dose in patients with chronic heart failure: which is the better target? Eur J Heart Fail. 2012;14:737–747.
   PubMed Web of Science ®Google Scholar
• Swedberg K, Komajda M, Bohm M, et al. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study. J Am Coll Cardiol. 2012;59:1938–1945.
   PubMed Web of Science ®Google Scholar
• Fiuzat M, Wojdyla D, Pina I, et al. Heart Rate or beta-blocker dose? Association with outcomes in ambulatory heart failure patients with systolic dysfunction: results from the HF-ACTION trial. JACC Heart Fail. 2016;4:109–115.
   PubMed Web of Science ®Google Scholar
• Coats AJ, Adamopoulos S, Radaelli A, et al. Controlled trial of physical training in chronic heart failure. Exercise performance, hemodynamics, ventilation, and autonomic function. Circulation. 1992;85:2119–2131.
   PubMed Web of Science ®Google Scholar
• O’Connor CM, Whellan DJ, Lee KL, et al. Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA. 2009;301:1439–1450.
   PubMed Web of Science ®Google Scholar
• Najem B, Unger P, Preumont N, et al. Sympathetic control after cardiac resynchronization therapy: responders versus nonresponders. Am J Physiol Heart Circ Physiol. 2006;291:H2647–H2652.
   Google Scholar
• Mangano DT, Layug EL, Wallace A, et al. Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. Multicenter study of perioperative Ischemia research group. N Engl J Med. 1996;335:1713–1720.
   PubMed Web of Science ®Google Scholar
• Poldermans D, Boersma E, Bax JJ, et al. The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. Dutch echocardiographic cardiac risk evaluation applying stress echocardiography study group. N Engl J Med. 1999;341:1789–1794.
   PubMed Web of Science ®Google Scholar
• Jakobsen CJ, Bille S, Ahlburg P, et al. Perioperative metoprolol reduces the frequency of atrial fibrillation after thoracotomy for lung resection. J Cardiothorac Vasc Anesth. 1997;11:746–751.
   PubMed Web of Science ®Google Scholar
• Lindenauer PK, Pekow P, Wang K, et al. Perioperative beta-blocker therapy and mortality after major noncardiac surgery. N Engl J Med. 2005;353:349–361.
   PubMed Web of Science ®Google Scholar
• Fleisher LA, Fleischmann KE, Auerbach AD, et al. 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: a report of the American college of cardiology/American heart association task force on practice guidelines. Circulation. 2014;130:e278–e333.
   PubMed Web of Science ®Google Scholar